REN-1189 | CAS# 183619-38-7 | TNF-a release inhibitor

MedKoo Cat#: 530215 | Name: REN-1189

Description:

WARNING: This product is for research use only, not for human or veterinary use.

REN-1189 is a TNF-a release inhibitor potentially for the treatment of sciatica and postherpetic neuralgia.

Chemical Structure

REN-1189

CAS#183619-38-7

Theoretical Analysis

MedKoo Cat#: 530215

Name: REN-1189

CAS#: 183619-38-7

Chemical Formula: C13H18N2O2

Exact Mass: 234.1368

Molecular Weight: 234.30

Elemental Analysis: C, 66.64; H, 7.74; N, 11.96; O, 13.66

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 350.00	2 Weeks
250mg	USD 550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

CPI-1189; REN-1189; REN-1654; CPI1189; REN1189; REN1654; CPI 1189; REN 1189; REN 1654

IUPAC/Chemical Name

4-acetamido-N-(tert-butyl)benzamide

InChi Key

DJKNRCWSXSZACF-UHFFFAOYSA-N

InChi Code

InChI=1S/C13H18N2O2/c1-9(16)14-11-7-5-10(6-8-11)12(17)15-13(2,3)4/h5-8H,1-4H3,(H,14,16)(H,15,17)

SMILES Code

O=C(NC(C)(C)C)C1=CC=C(NC(C)=O)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

REN-1189 can inhibit the activation of p38 mitogen activated protein kinase phosphorylation, and play a neuroprotective role.

In vitro activity:

REN-1189 alleviated oxygen glucose deprivation/re-oxygenation (OGDR)-induced programmed necrosis by inhibiting mitochondrial p53-cyclophilin D-adenine nucleotide translocase 1 association, mitochondrial depolarization, and lactate dehydrogenase release to the medium. REN-1189 potently inhibited OGDR-induced oxidative injury and neuronal cell death. Reference: Aging (Albany NY). 2021 Feb 17;13(5):6712-6723. https://pubmed.ncbi.nlm.nih.gov/33621193/

In vivo activity:

In this paper, REN-1189 is shown to mitigate apoptosis induced by TNFa, gp120, and necrosis induced by quinolinic acid. REN-1189 mitigates the cell death produced by supernatants from cultured macrophages obtained from patients with AIDS dementia. These findings may have implications for other neurological diseases where apoptotic cell death contributes to neurodegeneration. Reference: Brain Res. 2001 Mar 2;893(1-2):95-103. https://pubmed.ncbi.nlm.nih.gov/11222997/

	Solvent	mg/mL	mM
Solubility
	DMSO	47.0	200.61
	Ethanol	15.0	64.02

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 234.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Li YJ, Zhan Y, Li C, Sun J, Yang C. CPI-1189 protects neuronal cells from oxygen glucose deprivation/re-oxygenation-induced oxidative injury and cell death. Aging (Albany NY). 2021 Feb 17;13(5):6712-6723. doi: 10.18632/aging.202528. Epub 2021 Feb 17. PMID: 33621193; PMCID: PMC7993696. 2. Hensley K, Robinson KA, Pye QN, Floyd RA, Cheng I, Garland WA, Irwin I. CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties? Neurosci Lett. 2000 Mar 10;281(2-3):179-82. doi: 10.1016/s0304-3940(00)00861-2. PMID: 10704772. 3. Pulliam L, Irwin I, Kusdra L, Rempel H, Flitter WD, Garland WA. CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation. Brain Res. 2001 Mar 2;893(1-2):95-103. doi: 10.1016/s0006-8993(00)03293-5. PMID: 11222997. 4. Bjugstad KB, Flitter WD, Garland WA, Philpot RM, Kirstein CL, Arendash GW. CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex. J Neurovirol. 2000 Dec;6(6):478-91. doi: 10.3109/13550280009091948. PMID: 11175320.

In vitro protocol:

In vivo protocol:

1. Pulliam L, Irwin I, Kusdra L, Rempel H, Flitter WD, Garland WA. CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation. Brain Res. 2001 Mar 2;893(1-2):95-103. doi: 10.1016/s0006-8993(00)03293-5. PMID: 11222997. 2. Bjugstad KB, Flitter WD, Garland WA, Philpot RM, Kirstein CL, Arendash GW. CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex. J Neurovirol. 2000 Dec;6(6):478-91. doi: 10.3109/13550280009091948. PMID: 11175320.

1: Müller T. CPI-1189. Centaur. Curr Opin Investig Drugs. 2002 Dec;3(12):1763-7. Review. PubMed PMID: 12528314. 2: Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, Letendre S, Cohen BA, Marder K, Ellis RJ, Marra CM; Neurologic AIDS Research Consortium.. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology. 2002 Nov 26;59(10):1568-73. PubMed PMID: 12451199. 3: Bjugstad KB, Flitter WD, Garland WA, Philpot RM, Kirstein CL, Arendash GW. CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex. J Neurovirol. 2000 Dec;6(6):478-91. PubMed PMID: 11175320. 4: Pulliam L, Irwin I, Kusdra L, Rempel H, Flitter WD, Garland WA. CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation. Brain Res. 2001 Mar 2;893(1-2):95-103. PubMed PMID: 11222997. 5: Hensley K, Robinson KA, Pye QN, Floyd RA, Cheng I, Garland WA, Irwin I. CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties? Neurosci Lett. 2000 Mar 10;281(2-3):179-82. PubMed PMID: 10704772. 6: Bayes M, Rabasseda X, Prous JR. Gateways to Clinical Trials. June 2002. Methods Find Exp Clin Pharmacol. 2002 Jun;24(5):291-327. Review. PubMed PMID: 12168506. 7: Bjugstad KB, Flitter WD, Garland WA, Su GC, Arendash GW. Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Res. 1998 Jun 8;795(1-2):349-57. PubMed PMID: 9622673.